Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
University of California, San Diego
120 participants
Feb 19, 2024
INTERVENTIONAL
Conditions
Summary
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment.
Eligibility
Inclusion Criteria7
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Stable asthma medications: No change in asthma medications for the past 2 months:
- Use of medium or high dose inhaled corticosteroids (ICS) AND
- Use of an additional asthma controller medication.
- Baseline poor or uncontrolled asthma.
- Evidence of asthma demonstrated by either bronchodilator reversibility (either at screening or by historical evidence) or methacholine responsiveness (by historical evidence).
- Agreement to adhere to Lifestyle Considerations throughout study duration.
Exclusion Criteria23
- Current participation in an interventional trial (e.g. drugs, diets, etc.).
- Currently on an asthma biologic or having been on biologic within 3 months of screening.
- Enrollment in a clinical trial where the study medication was administered within the past 60 days or within 5 half-lives (whichever is greater).
- Physician diagnosis of other chronic pulmonary disorders associated with asthma-like symptoms, including, but not limited to, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways.
- Receiving one or more immune-modulating therapies for diseases other than asthma. This includes biologics that are also approved for asthma.
- Receiving methotrexate, mycophenolate (CellCept®), or azathioprine (Imuran®).
- Receiving aero allergen immunotherapy and not on at least 3 months of maintenance allergen immunotherapy.
- Underwent a bronchial thermoplasty within the last two years.
- Born before 30 weeks of gestation.
- Uncontrolled hypertension, defined as systolic blood pressure \> 160 mm/Hg or diastolic blood pressure \> 100 mm/Hg.
- History of malignancy except non-melanoma skin cancer within the last five years.
- History of smoking:
- If \<45 years old: Smoked for ≥5 pack-years\*
- If ≥45 years old: Smoked ≥ 10 pack years.
- Active use of any inhalant \>1 time per month in the past year.
- Substance abuse within the last year.
- Unwillingness to practice medically acceptable birth control or complete abstinence during the study, current pregnancy, or lactation.
- Requirement for daily systemic corticosteroids at the time of screening.
- Respiratory infection within 1 month of screening.
- Intubation for asthma in the last 12 months.
- Any clinically significant abnormal findings in the history, physical examination, vital signs, electrocardiogram, hematology or clinical chemistry during run-in period, which in the opinion of the site investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
- BMI \> 38.
- Allergic to any of the drugs, biologics or chemicals used in this study.
Interventions
Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W). Participants may self-administer injection after proper training.
Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W). Participants may self-administer injection after proper training.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06385236